Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Depreciation & Amortization (CF) (2016 - 2021)

Rhythm Pharmaceuticals (RYTM) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $201000.0 as the latest value for Q1 2021.

  • Quarterly Depreciation & Amortization (CF) rose 20.36% to $201000.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $201000.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $690000.0 for FY2020, 17.27% down from the prior year.
  • Depreciation & Amortization (CF) for Q1 2021 was $201000.0 at Rhythm Pharmaceuticals, up from $172000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $245000.0 in Q1 2019, with the low at $54000.0 in Q1 2017.
  • Average Depreciation & Amortization (CF) over 5 years is $138250.0, with a median of $169500.0 recorded in 2020.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 301.64% in 2019, then plummeted 31.84% in 2020.
  • Over 5 years, Depreciation & Amortization (CF) stood at $60000.0 in 2017, then skyrocketed by 256.67% to $214000.0 in 2018, then decreased by 10.75% to $191000.0 in 2019, then decreased by 9.95% to $172000.0 in 2020, then rose by 16.86% to $201000.0 in 2021.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $201000.0, $172000.0, and $173000.0 for Q1 2021, Q3 2020, and Q2 2020 respectively.